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Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood cancer that comprises
10–15% of pediatric and ~25% of adult ALL cases. Although the curative rates have significantly
improved over the past 10 years, especially in pediatric patients, T-ALL remains a challenge from a
therapeutic point of view, due to the high number of early relapses that are for the most part resistant
to further treatment. Considerable advances in the understanding of the genes, signaling networks,
and mechanisms that play crucial roles in the pathobiology of T-ALL have led to the identification
of the key drivers of the disease, thereby paving the way for new therapeutic approaches. PTEN is
critical to prevent the malignant transformation of T-cells. However, its expression and functions
are altered in human T-ALL. PTEN is frequently deleted or mutated, while PTEN protein is often
phosphorylated and functionally inactivated by casein kinase 2. Different murine knockout models
recapitulating the development of T-ALL have demonstrated that PTEN abnormalities are at the
hub of an intricate oncogenic network sustaining and driving leukemia development by activating
several signaling cascades associated with drug-resistance and poor outcome. These aspects and
their possible therapeutic implications are highlighted in this review.
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1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignant disorder that
represents ~25% of acute lymphoblastic leukemia cases in adults [1] and 10–15% in children [2].
Thanks to the use of an intensive combination chemotherapy and modulation of treatment tailored on
patient response, the overall survival at five years from diagnosis in pediatric patients has improved
to ~80% [3]. However, adults younger than 60 years have five-year survival rates of only 40–50%,
whereas older patients display an even worse outcome [4]. Furthermore, among children who relapse
and develop refractory leukemia, only about 20% can be successfully treated with currently-available
salvage treatments [5]. Moreover, especially children who survive T-ALL are at increased risk of
developing secondary neoplasias and other health problems due to the use of high-intensity genotoxic
chemotherapy [6]. Hence, more efficacious and less toxic novel treatments are needed for improving
the outcome of T-ALL patients and their quality of life, both during and after polychemotherapy.
Cancers 2019, 11, 629; doi:10.3390/cancers11050629 www.mdpi.com/journal/cancers
Cancers 2019, 11, 629 2 of 21
From a genetic point of view, T-ALL is a very heterogeneous disorder caused by the accumulation
of mutations that combine with altered expression of transcription factors during the development of
T-cells, thereby leading to aberrant activation of several signaling pathways [7,8]. The analysis of gene
expression profiles has allowed the identification of three major subgroups of T-ALL. These subgroups
display gene expression patterns closely related to those detectable during thymocyte differentiation [8].
Early T-cell precursor T-ALL (ETP T-ALL) has a gene expression profile typical of immature T-cell
precursors, very similar to hematopoietic stem cells (HSCs)/myeloid progenitors. Remarkably, ETP-ALL
patients display a pattern of genetic anomalies overlapping with that of acute myeloid leukemia,
including Fms-related tyrosine kinase 3 (FLT3) mutations [9]. Early cortical thymocyte T-ALL is usually
associated with chromosomal translocations that lead to the aberrant expression of nuclear receptor
subfamily 2 group E member (TLX) 1/3 and the related homeobox (HOX) transcription factor family of
oncogenes [7]. Late cortical T-ALL is the largest subgroup, accounting for 40–60% of all cases, and
typically overexpresses the transcription factor oncogene T-cell acute lymphocytic leukemia 1 (TAL1)
with either LIM domain only (LMO) 1 or LMO2 [10].
The phosphatase and tensin homolog, deleted on chromosome TEN (PTEN), is one of the
most frequently-mutated/functionally-inactivated oncosuppressors in cancer [11]. PTEN function
is lost in a wide variety of human cancers (breast, thyroid, colorectal, endometrial, lung, bladder,
melanoma) through somatic mutations, gene silencing, epigenetic alterations, and post-translational
modifications that include phosphorylation, oxidation, acetylation, and ubiquitination [12]. PTEN
is an inositol lipid phosphatase that dephosphorylates phosphatidylinositol (3,4,5)P3 (PIP3) to
yield phosphatidylinositol(4,5)P2 (PIP2). Therefore, PTEN acts as the main negative regulator of
the phosphatidylinositol-3 kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling
network [13]. This cascade plays key roles in the control of a wide range of processes that
include cell proliferation, survival, growth, motility, metabolism, and angiogenesis [14]. In general,
PI3K has per se a weak driver oncogenic activity, although its upregulation is permissive for
growth factor signals via cooperation with other signaling pathways, such as the more potent
rat sarcoma (RAS)/rapidly-accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase
(MEK)/extracellular signal-regulated kinase (ERK) module [15]. However, in genetically-engineered
murine models, several studies have documented a causal role of mutated PI3K on initiation,
progression, and maintenance in some types of neoplasia that include lung and breast cancer [16,17].
In contrast, in other cell types, such as ovarian cells, knock-in of mutated, constitutively-active
p110α PI3K resulted in cell hyperplasia, but not invasive cancer. Nevertheless, concomitant PTEN
deletion led to the development of serous ovarian adenocarcinoma [18]. These findings suggest
that in some cell types, PTEN loss may cooperate with other genetic alterations to induce cancer
development. Furthermore, germline PTEN mutations are responsible for the rare, cancer-prone
syndromes collectively referred to as PTEN hamartoma tumor syndrome, characterized by various
benign and malignant tumors (breast, endometrial, thyroid, renal, and colon) [19].
PTEN has PI3K-independent functions, being involved in genome stability, chromatin remodeling,
and double-strand DNA breaks’ repair [12], although the molecular mechanisms that regulate these
functions are far from being fully understood [20]. Nevertheless, PTEN anomalies have been shown to
contribute to endometrial carcinogenesis through defective DNA repair [21].
PTEN could also act as a protein phosphatase, as it is capable of dephosphorylating both
phospho-serine/threonine and phospho-tyrosine residues [22]. Focal adhesion kinase (FAK) is one of
the few PTEN protein substrates that have been identified [23].
In recent years, three additional PTEN variants have been identified: PTEN-long [24],
PTENα [25], and PTENβ [26]. PTEN-long is secreted outside the cell, can be detected in human
plasma, and plays an important role in the control of PTEN-induced putative kinase protein 1
(PINK1)-catalyzed phosphorylation of ubiquitin [27]. PTENα regulates mitochondrial functions and
energy metabolism [25], as well as neutrophil chemotaxis [28], while PTENβ localizes predominantly
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to the nucleolus where it associates with and dephosphorylates nucleolin, thereby acting as a negative
regulator of rDNA transcription [26].
Although the roles of PTEN as a tumor suppressor have been extensively documented and are
well established, accumulating evidence indicates that PTEN functions are of fundamental importance
in regulating physiological processes in healthy HSCs [29] and intestinal stem cells [30], as well as in
normal T-, B-, and NK-cells [31–34]. Checking PI3K signaling is particularly important, as excessive
levels of PIP3 not only oppositely affect many of the same processes, but can also somehow transform
cells (for example HSCs) and lead to cancer [35].
Regarding T-cells, by limiting the amount of PIP3 available within the cell, PTEN directly
opposes the PI3K/Akt/mTOR axis, thereby influencing the selection of developing thymocytes,
as well as the activation of mature T-lymphocytes. T-cells with uncontrolled PI3K/Akt/mTOR
activity, as a result of PTEN loss, contribute to the development of both autoimmune disorders and
lymphomas [36]. For instance, T-cell–selective deletion of Pten leads to a premalignant state in the
CD4+CD8+ double-positive thymocyte population that is followed by development of CD4+ T-cell
lymphomas in secondary lymphoid organs, including the lymph nodes and the spleen [37–39].
PTEN is often inactivated via different mechanisms in human T-ALL, where it can be associated
with chemotherapy and targeted therapy resistance, as well as a poor prognosis [40].
In this review, we discuss how PTEN-loss-of-function drives and sustains T-ALL via the activation
of multiple signaling pathways. A better knowledge of the regulation of these networks could be of
fundamental importance in their exploitation for an improved therapy and outcome of T-ALL.
2. PTEN and T-ALL Development in Mice
The observation that Pten−/− mice showed an embryonic lethal phenotype [41] prompted
several groups to develop conditional knockout models, where Pten was selectively targeted in
HSCs/hematopoietic progenitor cells/T-cells [42].
2.1. PTEN Conditional Deletion in HSCs
Several studies have demonstrated that Pten loss in HSCs/hematopoietic progenitor cells invariably
causes T-ALL development (although with a different penetrance, depending on the model used) that is
preceded by a myeloproliferative disorder [35,43–45]. In particular, Guo and coworkers [44] showed that
Pten conditional deletion in murine HSCs from fetal liver led to a T-ALL where self-renewable leukemia
initiating cells (LICs) were enriched in the c-Kitmid/CD3+/Lin− bone marrow (BM) compartment.
These LICs were capable of driving T-ALL development in four serial cohorts of mice and displayed
significantly increased unphosphorylated β-catenin levels that sustained their renewal. Importantly,
when one of the alleles of the β-catenin gene was ablated, the incidence of T-ALL caused by the loss of
Pten substantially decreased, while leukemia progression was delayed in those mice that still developed
the disorder. However, it should be emphasized here that treatment of this Pten-null T-ALL model
with PI3K inhibitors was effective prior to the onset of leukemia, but not after leukemia was already
underway [46,47]. This observation suggests that Pten ablation is not responsible for maintaining
LSC stemness features, once LICs have been generated. In this context, it is important to underline
that recent findings have highlighted how self-renewal of T-ALL LICs is driven and maintained by
β-catenin via a spleen focus-forming virus proviral integration oncogene 1 (SPI1)/hepatitis A virus
cellular receptor 2 (HAVCR2) regulatory circuit [48] (see later on in this article). T-ALL LICs displayed
a chromosomal translocation involving T-cell receptor α/δ and c-Myc (Tcrα/δ-c-Myc), which resulted
in aberrant overexpression of the avian myelocytomatosis viral homolog (c-MYC) oncogene [44].
These findings are extremely interesting as c-MYC translocations involving the T-cell receptor (TCR)
loci have been identified in a small (~3%) subset of T-ALL patients displaying poor prognostic
markers [49]. Importantly, the T-ALL LICs identified by Guo and coworkers [44] could be eradicated
by co-targeting with selective inhibitors the deregulated pathways driven by PI3K and c-MYC [47].
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Remarkably, at variance with adult stem cells, Pten deletion did not activate PI3K signaling or
promote leukemogenesis in neonatal HSCs, thereby indicating that developmental stage dictates the
tumor-suppressive functions of PTEN [50]. Miething et al. [51] exploited a transgenic mouse model
where Pten expression in HSCs was regulated in both a time- and tissue-specific manner, to show that
PTEN loss in the postnatal period sensitized T-ALL cells to C-C chemokine ligand 25 (CCL25), which
is mainly expressed in mucosal epithelial cells in the small intestine. By interacting with its receptor
C-C chemokine receptor 9 (CCR9, which was found to be highly expressed on Pten-null leukemic
cells), CCL25 drove leukemic cell infiltration into the intestine, but not into other organs, such as the
liver or the spleen [51]. Therefore, also signals originating from the microenvironment could strongly
influence PTEN-loss-induced leukemogenesis, by producing a form of intratumoral heterogeneity.
PTEN loss characterizes a murine model of T-ALL where leukemogenesis was induced by
overexpression of constitutively-active tropomyosin-related kinase A (∆TRKA) or of TRKB/brain-
derived neurotrophic factor (BDNF, the TRKB ligand) in Lin−/Sca1+/c-Kit+ HSCs [52]. During clonal
evolution, these T-ALL cells acquired activating mutations in neurogenic locus notch homolog protein 1
(NOTCH1) and lost PTEN function due to loss of either one or both Pten alleles. Moreover, Pten
inactivating mutations in exons 5 and 6 were detected in some clones. These findings show that PTEN
loss can also be a secondary genetic lesion acquired during T-ALL clonal evolution.
Bornschein and coworkers [53] took advantage of a recently-developed murine pro-T-cell culture
system [54] for unraveling the mechanisms underlying the cooperation between TAL1 transcription
factor overexpression and Pten deletion, i.e., a combination of abnormalities frequently observed in
T-ALL patients (see further on in this review) [55,56]. This system was used to demonstrate that
the cooperation between TAL1 overexpression and Pten deletion resulted in an upregulated stem
cell-like gene signature and increased E2 transcription factor (E2f) signaling activity and metabolic
reprogramming characterized by higher lactate levels due to an increased flux of glucose into the
tricarboxylic acid cycle [53]. Surprisingly, TAL1 overexpression per se was a growth disadvantage to
pro-T-cells that could be, however, relieved by Pten deletion that induced Akt activation and expression
of c-MYC and E2f. These findings emphasize how the signaling networks of healthy T-cells can be
altered and/or taken over by the oncogenic events that characterize T-ALL.
2.2. PTEN Conditional Deletions in T-Cells
The use of transgenic murine cell lines where Cre recombinase is under the control of T-cell-specific
promoters allowed several groups to demonstrate that the developmental stage of T-cells is critical
for the outcome of Pten loss. Pten ablation in the double-negative thymocyte population led to the
development of T-cell lymphomas that caused the death of the animals within 10–17 weeks. [37,39,57,58].
Nevertheless, T-cell lymphomas were also observed when Pten was ablated at later stages of thymocyte
development, by using the CD4-Cre system [38]. Very recently, it was shown that human primary
T-ALL cells expressing αβTCR are frequently deficient for PTEN and fail to respond strongly to
TCR activation [59]. It is well known that signaling through αβTCR is a fundamental determinant
of thymocyte fate and can result in two opposite outcomes during T-cell development: cell death
or survival/differentiation [60]. However, the exact roles played by TCR in the transformation of
developing T-cells remain to be defined [61]. Using Pten-null T-ALL murine models, it was shown that
abrogation of TCR accelerated cancer development, whereas the overexpression of a fully-functional [62]
transgenic αβTCR led to the onset of TCR-negative lymphomas while delaying tumorigenesis [59].
This group also demonstrated that pre-neoplastic Pten-null thymocytes with a fully-functional αβTCR
underwent early clonal deletion and did not progress to neoplastic cells. In contrast, cells with a
non-functional αβTCR that are normally deleted in the positive selection process in the thymus passed
selection and developed T-ALL. Altogether, these findings document that a fully-functional αβTCR
signaling suppresses leukemogenesis caused by Pten ablation and suggest that PTEN likely plays a
fundamental role during positive selection [59]. In contrast, another group had previously shown that
the loss of γcTCR inhibited thymic exit of Pten-deficient T-cells [63].
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On the other hand, Pten deletion did not cause the development of T-cell lymphomas in either CD4+
helper T-cells or peripheral T-cells [64,65]. The aforementioned results unequivocally demonstrate
that neoplastic transformation occurs only if Pten is deleted during thymocyte development, but not
in mature, peripheral T-lymphocytes, thereby supporting the hypothesis that the tumor suppressor
functions of PTEN are tightly dependent on the developmental stage of T-cells.
2.3. Studies in Human T-ALL Cells
The findings obtained with murine models have been partially confirmed when primary human
T-ALL cells of a patient who relapsed and displayed a PTEN deletion at relapse, but not at diagnosis,
were xenografted in mice. PTEN knockdown via shRNA in leukemic cells obtained at diagnosis
conferred a selective advantage in competitive xenotransplantation experiments. These findings
hint that PTEN loss in human T-ALL could promote the expansion of leukemic clones endowed
with upregulated LIC activity, although in this case, PTEN deletion could not be the initial driving
force for T-ALL development [66]. More recently, PTEN loss has been analyzed in human T-ALL
samples displaying the stem cell leukemia (SCL)/TAL1 interrupting locus (STIL) protein/TAL1 fusion
product [67] that were xenografted in mice and compared with specimens collected at diagnosis [68].
PTEN loss was detected as a secondary event in some subclones of leukemic cells.
Overall, these two studies seem to suggest that PTEN loss in human T-ALL is unlikely to be a
founder or truncal mutation, but rather part of additional genomic lesions that may be critical for
increased malignancy, as well as for clonal selection of the leukemic cells. It is worth emphasizing here
that this experimental approach reproduces quite faithfully the process of leukemia progression from
diagnosis toward relapse.
3. PTEN Regulation in Human T-ALL
Over the years, it has become clear that both genetic and non-genetic mechanisms lead to
PTEN-loss-of-function in human T-ALL cells.
3.1. Genetic Mechanisms of PTEN Inactivation
PTEN-loss-of-function is due to predominantly monoallelic point mutations, gene deletions,
or micro-deletions [4,55,69–79]. The frequency of PTEN alterations is variable, most likely due to
differences in patient cohort size and/or methodology used; however, they have been detected in
11–27% of childhood T-ALL cases and 5–17% of adult patients. In children, PTEN mutations were
mostly identified in TAL/LMO patients, although the association was not significant, while the incidence
of mutations was significantly lower in the TLX cluster [55,71]. In adults, PTEN abnormalities
were more frequently detected in younger, TCR-positive, STIL/TAL1-positive, NOTCH1/F-box WD
repeat-containing protein 7 (FBXW7) unmutated patients with high leukemic bulk tumors [72].
Point mutations almost invariably affect exon 7 of PTEN that partially encodes the C2-domain [69,
70]. Interestingly, these mutations seem to be specific to human T-ALL, as in other types of cancer,
the hotspot for mutations is at exon 5, which encodes the phosphatase domain of PTEN [80]. Point
mutations at exon 7 lead to carboxy terminal truncation of PTEN and are associated with reduced or
lost PTEN expression in T-ALL patients [71,72], as truncated PTEN undergoes rapid degradation [81]
via the ubiquitin-mediated proteasomal pathway [82].
The phosphatase domain-coding exons (2–6) display heterogeneously-sized deletions in about
3–8% of pediatric and adult T-ALL patients. These deletions affect almost exclusively exon 2 [69,71,72].
Furthermore, a detailed analysis of a large cohort of childhood T-ALL patients has led to the discovery
of microdeletions, originating from illegitimate recombination events (see later in this article), in exons
2/3 and 4/5 [74]. Such microdeletions were detected in about 8% of patients.
Interestingly, when PTEN alterations were studied in a pediatric cohort, 67% of the cases displayed
more than one PTEN anomaly, with some patients having up to four alterations [75]. These findings
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suggest the existence of multiple leukemic subclones displaying various PTEN anomalies, with each of
these subsets possibly having different biological and clinical features.
3.2. Non-Genetic Mechanisms of PTEN Inactivation
Aberrant splicing of PTEN transcripts has been rarely detected in both pediatric [71] and adult [83]
T-ALL patients. The exact origin of these defective events remains to be determined, as there were no
mutations found in the first 20–30 intronic bases that flanked the splice donor/acceptor sites of the
affected exons. However, defective splicing resulted in abolished PTEN expression [71].
PTEN is negatively regulated at the transcriptional level via aberrant NOTCH1 signaling, one of
the major regulatory pathways of growth and metabolism in T-ALL cells [84]. The NOTCH1 signaling
downstream target, hairy and enhancer of split-1 (HES-1), represses PTEN transcription by occupying
regulatory sequences of the PTEN promoter [83].
In cancer cells, PTEN levels can be downregulated either epigenetically or post-transcriptionally
by non-coding RNAs, including microRNAs (miRs) [85]. In murine T-ALL cells, miR-19 represses PTEN
expression [86]. Although this oncogenic miR is highly expressed in human T-ALL cells [87], its ability
to downregulate PTEN in this setting has not been demonstrated yet. Other miRs identified in human
T-ALL and potentially targeting PTEN [88,89] include miR-20a and miR-92 [90], miR-148 [91], and
miR-20b-5p and miR-363-3 [79]. Therefore, all of these miRs might contribute to the pathophysiology
of T-ALL via downregulation of PTEN.
In T-ALL cells, PTEN protein is inactivated via posttranslational mechanisms that include
both oxidation by reactive oxygen species (ROS) [92] and phosphorylation by casein kinase
2 (CK2) [92,93]. In particular, CK2 phosphorylates a cluster of serine/threonine residues
(Ser370/Ser380/Thr382/Thr383/Ser385) located at the C-tail of the PTEN molecule [94,95]. Ser370/Ser385 are
the most important residues for CK2-mediated downregulation of PTEN activity towards its substrate,
PIP3 [96]. This results in higher PIP3 levels and PI3K/Akt activation [92].
4. Oncogenetic Functions of PTEN in T-ALL Cells
4.1. PI3K-Dependent Functions
PTEN loss-induced leukemogenesis has been mostly related to the activation of the
PI3K/Akt/mTOR network (Figure 1). Indeed, upregulated PI3K/Akt/mTOR signaling has been
consistently observed in human T-ALL specimens with PTEN mutations and/or deletions [72,83,97].
Moreover, several lines of evidence indicate that this signaling pathway is critically involved in
the development of T-cell malignant disorders that follow PTEN loss in mouse models [98–101].
In particular, regarding PI3K, it has been shown that the p110γ and p110δ PI3K catalytic subunits
cooperatively sustain leukemogenesis in Pten-mutant mice [101]. Of note, recent findings have
demonstrated that PTEN represses PI3K/Akt signaling also via an Ikaros transcription factor/miR-26b
axis that directly downregulates the expression of PIK3CD, i.e., the gene encoding the p110δ PI3K
catalytic subunit [102] (Figure 1).
Nevertheless, the precise roles played by Akt activation downstream of PTEN loss in mice are
still awaiting to be fully elucidated as, surprisingly, phosphoinositide-dependent kinase 1 (PDK1)/Akt
signaling was not required for the proliferation of Pten-null thymocytes [99]. Consistently, expression of
constitutively-active Akt in transgenic mouse thymocytes did not impact on their cell cycle distribution
in vivo [103]. It might be that PDK1/Akt signaling is implicated in processes different from cell
proliferation, such as thymocyte migration to secondary lymphoid organs through the control of
chemokines and adhesion receptors expressed by PTEN-null cells [99].
Nevertheless, by activating Akt, PTEN loss downregulates glycogen synthase kinase 3β (GS3Kβ)
activity, thereby preventing c-MYC degradation mediated by GS3Kβ [104]. Accordingly, there is an
inverse correlation between c-MYC expression levels and PTEN expression in samples from T-ALL
patients [105]. In mice, c-MYC activates aurora kinase B, which is somehow involved in the regulation
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of self-renewal of Pten-null LICs [47] (Figure 1). However, the regulation and maintenance of the
key determinants of stemness in T-ALL LICs is a complex phenomenon. For instance, in a recent
paper, Zhu et al. [48] identified SPI1 as a master regulator of LIC stemness in a murine Pten-null
T-ALL model. This group demonstrated that Spi1 expression is initiated by the PTEN-controlled
β-catenin overactivation characterizing murine Pten-null T-ALL. However, both Spi1 expression
and LIC stemness were reinforced and maintained via a β-catenin-SPI1-HAVCR2 regulatory circuit
independently of the leukemogenic driver mutation. Altering any component of this circuit either
genetically or pharmacologically prevented LIC formation or eliminated existing LICs, whereas
inhibition of the PI3K/Akt pathway had little effect on the LIC number. LICs lost their stem cell features
when Spi1 expression was silenced by DNA methylation; however, Spi1 expression could be reactivated
by treatment with the DNA methyltransferase inhibitor, 5-azacytidine. Of note, similar regulatory
circuitries could be also detected in human T-ALL cells [48].
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It is worth highlighting here that in humans, SPI1 encodes the PU-box 1 protein (PU.1), one
of the most important members of the E-twenty-six (Ets) transcription factor family. PU.1 plays a
broad range of roles in hematopoiesis, including the early stages of T-cell development [106], where
its overexpression induces progenitor T-cell proliferation while blocking differentiation [107,108].
Importantly, gene fusions involving SPI-1 were detected in ~4% of 181 pediatric T-ALL cases displaying
a characteristic gene expression profile and a uniformly poor overall survival [108].
LIC self-renewal also requires mTOR [46,47]. mTOR acts as the catalytic subunit of two
distinct multiprotein complexes, known as mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2) [109,110]. Of these, the first one is probably involved in regulating LIC self-renewal, as
leukemic clones with upregulated LIC activity displayed increased mTORC1 activity in a T-ALL
zebrafish model [111]. Nevertheless, both mTORC1 and mTORC2 are likely involved in T-ALL
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development, as ablation of either raptor (an mTORC1 component) or rictor (an mTORC2 component)
increased the survival of Pten-mutant mice in a significant manner [50,112]. mTORC1 controls key
cellular functions that include mRNA translation, metabolism, and autophagy, while mTORC2 is mainly
involved in cell survival and motility [113–116]. mRNA translation sustains T-cell development in vivo,
as, when ribosome function was reduced in Pten-mutant mice by expressing a mutated ribosome
protein L24 (Rpl24), protein synthesis was downregulated, thereby decreasing leukemogenesis [117].
mTORC1 upregulates mRNA translation mainly through the phosphorylation of the translation
initiation component eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and 70-kDa
ribosomal protein S6 kinase (p70S6K) [118] (Figure 1). Both 4E-BP1 and p70S6K seem to play a role in
T-ALL, although p70SK deficiency in Pten-null HSCs only slightly delayed leukemia initiation [52,119].
4.2. PI3K-Independent Functions
The existence of a protein phosphatase activity of PTEN is highly controversial; however, PTEN
could restrain FAK activity by dephosphorylation [23,120]. Upregulated FAK activity was observed in
bothPten-deleted murine thymocytes and human PTEN-null T-ALL cells [121], where it elicited survival
signals via a receptor activating protein 1 (RIP1)/nuclear factor-κB (NF-κB)/B-cell lymphoma-extra-large
(Bcl-xL)/B-cell lymphoma 2 (Bcl-2) signaling axis [122] (Figure 1). Moreover, when FAK was deleted
in Pten-mutated hematopoietic progenitor cells, T-ALL development was significantly delayed.
Interestingly, it was demonstrated that FAK was activated via interactions with the extracellular matrix
(ECM) and integrins in PTEN-mutated T-ALL cells (Figure 1). Consistent with the existence of two
parallel signaling cascades leading to survival of leukemic cells, treatment with FAK pharmacological
inhibitors increased the sensitivity of murine and human PTEN-null T-ALL cells to drugs targeting the
PI3K/AKT/mTOR pathway, both in vitro and in vivo [121]. Although it is still unclear how PTEN could
downregulate FAK activity, these results indicate that both the PI3K-dependent and -independent
functions of PTEN are necessary to dampen T-cell malignant transformation.
4.3. Genomic Stability
PTEN has been defined as a guardian of the genome [20,123]. As previously highlighted in this
article, Pten ablation in murine HSCs or developing T-cells leads to chromosomal translocations between
the Tcrα/δ locus and the c-Myc oncogene. This observation suggests that PTEN may oppose genomic
instability [38,44,46,51]. In solid tumors, this function of PTEN is independent of its phosphatase
activity and requires PTEN translocation to the nucleus [20]. However, in T-ALL, PTEN controls
genome stability most likely via the activation of phosphatase-dependent cytosolic signaling networks,
as demonstrated by a study from Newton and coworkers [124]. This group developed an elegant
murine model where a phosphatase-dead PTEN-mutant form was overexpressed in T-cells that lacked
wild-type PTEN. As a consequence, the mice developed a CD4+ T-cell lymphoma displaying the
typical Tcrα/δ-c-Myc chromosomal translocation. Although these findings demonstrate that PTEN
phosphatase activity is required to prevent genomic instability, the molecular basis underlying this
process remains unclear. Interestingly, thymocytes expressing the phosphatase-dead PTEN mutant
upregulated the Akt/forkhead box protein O (FoxO) axis and displayed a FoxO-dependent upregulation
of ROS levels that might contribute to DNA damage [125]. In this context, it is worth emphasizing that
active FoxO transcription factors counteract ROS generation by increasing the levels of antioxidant
enzymes [126,127]. However, once phosphorylated by Akt, FoxOs are no longer active [128]; hence,
ROS production could increase (Figure 2).
The genomic instability that characterizes Pten-null cells may also originate from an aberrant
activation of β-catenin, as β-catenin upregulation prevented the repair of recombination activating
gene (RAG)-mediated DNA double-strand breaks in murine thymocytes, thus leading to Tcrα-δ/c-Myc
translocations and T-cell lymphoma development [129] (Figure 2). The activation of β-catenin in
the context of PTEN-loss-of-function could be due to enhanced PI3K/Akt signaling and subsequent
downregulation of GSK3β, which is a well-known repressor of β-catenin [130] (Figure 2).
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Moreover, if RAG1 recombinase was knocked out in Pten-mutated HSCs, Tcrα/δ-c-Myc
translocations, LIC formation, and T-ALL development were blocked. These observations indicate that
the loss of Pten induces a genomic instability that is critical for T-cell malignant transformation [46].
Of note, also the PTEN microdeletions identified in some pediatric T-ALL cases by Mendes and
coworkers [74] occur as a consequence of aberrant RAG-mediated recombination events.
Cancers 2019, 11, x 9 of 21 
 
,          -c-  
l cations, LIC formation, and T-ALL d velopment were blocked. These observations indicate 
at the loss of Pten induces a genomic instability that is critical for T-ce l m lignant transformation 
[46]. Of note, also the PTEN microdeletions identified in some pediatric T-A L cases by endes  
 ]    c  f rr t - e iate  reco bination events. 
 
Figure 2. Genomic instability as a consequence of PTEN-loss-of activity in T-ALL cells. When PTEN 
activity is lost, active Akt phosphorylates and inhibits both GSK3β and the FoxO family of transcription 
factors. Inhibition of GSK3β leads to β-catenin activation and downregulation of double-strand break 
DNA repair mediated by RAG1. Moreover, upregulated ROS levels, due to decreased FoxO 
transcription factor activity, determine DNA damage. As a consequence, the typical Tcrα/δ-c-Myc 
chromosomal translocation occurs, resulting in increased expression of c-MYC. 
5. Clinical Impact of PTEN Loss on T-ALL Patient Outcome 
Several groups have addressed the prognostic impact of PTEN loss in a number of pediatric and 
adult T-ALL patient cohorts [4,69–73,75,77,78,131–133]. In general, PTEN anomalies have been 
associated with poor response to chemotherapy, increased risk of relapse, and adverse long-term 
outcome in all of the studies except for three that were performed in childhood patient cohorts 
[75,131,132]. Interestingly, the unfavorable clinical effects of inactivating PTEN mutations in pediatric 
T-ALL patients could be neutralized by coexisting NOTCH1 activating mutations [73]. Another study 
that analyzed a large cohort of 573 pediatric and adult T-ALL patients treated with the GRAALL03/05 
and FRALLE2000 therapeutic protocols came to the intriguing conclusion that the prognostic impact 
of PTEN loss is likely dependent on the underlying type of genetic anomaly [77]. In particular, while 
large deletions predicted lower five-year overall survival and disease-free survival both in children 
and in adults, mutations could not be associated with a worse prognosis. These findings may indicate 
that a detailed analysis of the type of genetic anomaly would be useful to refine risk stratification 
based on PTEN status. However, in the most recently-published study, all types of PTEN 
abnormalities were found to be significantly linked to an unfavorable prognosis in a cohort of 162 
T-ALL pediatric cases treated with the ALL IC-BFM 2002 and 2009 therapeutic protocols [133]. 
Therefore, despite many efforts, the clinical impact of PTEN alterations is still an area of intense 
Figure 2. Geno ic instability as a consequence of PTE -loss-of activity in T- LL cells. hen PTE
activity is lost, active Akt phosphorylates and inhibits both GSK3β and the FoxO fa ily of transcription
factors. Inhibition of GSK3β leads to β-catenin activation and downregulation of double-strand
break DNA repair mediated by RAG1. Moreover, upregulated ROS levels, due to decreased FoxO
transcription factor activity, determine DNA damage. As a consequence, the typical Tcrα/δ-c-Myc
chromosomal translocation occurs, resulting in increased expression of c-MYC.
5. Clinical Impact of PTEN Loss on T-ALL Patient Outcome
Several groups have addressed the prognostic impact of PTEN loss in a number of pediatric
and adult T-ALL patient cohorts [4,69–73,75,77,78,131–133]. In general, PTEN anomalies have
been associated with poor response to chemotherapy, increased risk of relapse, and adverse
long-term outcome in all of the studies except for three that were performed in childhood patient
cohorts [75,131,132]. Interestingly, the unfavorable clinical effects of inactivating PTEN mutations
in pediatric T-ALL patients could be neutralized by coexisting NOTCH1 activating mutations [73].
Another study that analyzed a large cohort of 573 pediatric and adult T-ALL patients treated with
the GRAALL03/05 and FRALLE2000 therapeutic protocols came to the intriguing conclusion that the
prognostic impact of PTEN loss is likely dependent on the underlying type of genetic anomaly [77].
In particular, while large deletions predicted lower five-year overall survival and disease-free survival
both in children and in adults, mutations could not be associated with a worse prognosis. These findings
may indicate that a detailed analysis of the type of genetic anomaly would be useful to refine risk
stratification based on PTEN status. However, in the most recently-published study, all types of
PTEN abnormalities were found to be significantly linked to an unfavorable prognosis in a cohort of
162 T-ALL pediatric cases treated with the ALL IC-BFM 2002 and 2009 therapeutic protocols [133].
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Therefore, despite many efforts, the clinical impact of PTEN alterations is still an area of intense debate
and likely depends on the methods of analysis, as well as on the treatment context and the presence of
other genetic anomalies.
6. Therapeutic Perspectives
Glucocorticoids (GCs) represent an important component of the armamentarium we have at our
disposal for treatment of T-ALL and, in combination with other chemotherapeutic agents, contribute to
~80% of pediatric patients achieving long-term overall survival [134]. Early response to GCs predicts
a positive prognosis, while patients who do not show a robust response relapse more frequently
and experience a negative outcome [135]. Although the molecular basis underlying GC resistance in
T-ALL cells remains to be defined, several lines of evidence indicate the PI3K/Akt/mTOR axis as one
of the signaling networks involved in GC-resistance [111,136,137]. Active Akt impairs GC-induced
gene expression via the phosphorylation of the GC receptor, nuclear receptor subfamily 3 group C
member 1 (NR3C1), at Ser134. This phosphorylation blocks GC-dependent translocation of NR3C1
to the nucleus [97] (Figure 1). The selective Akt inhibitor, MK-2206, restored GC-induced NR3C1
nuclear translocation and reversed the response of PTEN-null T-ALL cells to GCs in vitro and in vivo.
Of the three Akt isoforms expressed in mammalian cells (Akt1, Akt2, Akt3), Akt2 seems to be the
most relevant to GC-resistance, as it was highly expressed in GC-resistant PTEN-null human T-ALL
cell lines. Importantly, GC-resistance could be reversed in vitro and in vivo by CCT128930, a highly
specific Akt2 inhibitor [138]. The pro-apoptotic protein Bcl-2-like protein 11 (Bim) is one of the
effectors of GC-mediated cytotoxicity, as its upregulated expression via Akt2 inhibition increased
GC-sensitivity [138]. Similar results had been previously reported by an independent group that used
the dual PI3K/mTOR inhibitor NVP-BEZ235 to counteract GC-resistance in PTEN-null human T-ALL
cells [139].
Regarding innovative therapies, numerous preclinical studies have demonstrated that inhibitors
selectively blocking PI3K activation are promising drugs for T-ALL treatment [140]. In PTEN-null
models of T-ALL, the dual p110γ/δ PI3K inhibitor, CAL-130, prolonged survival in an animal model.
Moreover, the drug blocked proliferation and activated proapoptotic signaling pathways in human
T-ALL cell lines and primary samples [101]. However, these findings could not be confirmed by
other groups that showed that inhibition of all four isoforms of the p110 PI3K catalytic subunit was
more effective than dual p110γ/δ PI3K inhibition in inducing cytotoxicity in human PTEN-null T-ALL
cells [141,142].
This discrepancy may partly depend on the fact that in human PTEN-null T-ALL, TRKB collaborates
with PTEN loss by activating both the PI3K/Akt and Janus kinase (JAK)/signal transducer and activator
of transcription 3 (STAT3) pathway. In particular, it was demonstrated that p110α and p110δ are the
major PI3K isoforms that mediate PI3K/Akt signaling evoked by TRKB activation in PTEN-null T-ALL
cells [143]. These findings are consistent with observations of other groups showing that TRKB promotes
survival and metastasis of lung adenocarcinoma, breast cancer, and chondrosarcoma by upregulating
PI3K/Akt and JAK/STAT3 signaling [144–146]. TRKB could be activated in PTEN-null T-ALLs by
an autocrine loop involving BDNF [52]. In neurons, PI3K does not directly bind TRKB [147,148].
However, when activated by its ligand BDNF, TRKB auto-phosphorylates tyrosine residues in its juxta
membrane domain. These residues are the docking sites for a wide variety of adaptor molecules,
including insulin receptor substrate (IRS)-1 and -2, which increase PI3K/Akt activity [147] (Figure 1).
Regarding JAK/STAT3 upregulation, it could also depend, at least in part, on secretion of cytokines that
is increased in cells lacking PTEN [143]. Interestingly, PI3K inhibitors alone had little effect on STAT3
phosphorylation in T-ALL cells, suggesting that JAK/STAT3 activation might drive a partial resistance
to PI3K inhibitors. Accordingly, a combined treatment consisting of PI3K and STAT3 inhibitors resulted
in maximal suppression of T-ALL cell proliferation and tumor progression in vivo. Of note, TRK family
receptors are rapidly emerging as potential therapeutic targets in various cancer types [149,150], and
TRK inhibitors are being tested in phase I/II trials [151,152].
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The NOTCH1 signaling pathway represents an attractive target to treat T-ALL, given that NOTCH1
is activated by mutations in 65–70% of T-ALL patients [153] and is a central driver of T-ALL cell survival,
growth, and metabolism [8]. NOTCH1 signaling can be effectively targeted by γ-secretase inhibitors
(GSIs) [154]. Pten loss in murine NOTCH1-mutated T-ALL cells drives an oncogenic addiction to
PI3K/Akt, which sustains leukemic cell growth independently of NOTCH1 signaling, thereby causing
resistance to GSI treatment [155]. In a murine model, Pten deletion activated the expression of multiple
genes involved in ribosomal RNA processing, amino acid, and nucleotide synthesis, likely due to
upregulation of mTORC1 activity. Expression of these genes is normally repressed in response to
treatment with GSIs. Moreover, Pten loss relieved the block of glycolysis and glutaminolysis induced by
GSIs, a phenotype that could be mimicked by overexpression of a constitutively active form of Akt [155].
Clinical trials with GSIs have so far given disappointing results in T-ALL patients, due to several
issues [156,157]. However, in light of the previously-reported findings, future NOTCH1-targeted
therapies might be more efficacious if GSIs could be combined with either PI3K or Akt inhibitors [40].
Rapamycin, an mTORC1 inhibitor, has proven its efficacy to eradicate LICs in PTEN-null preclinical
models of murine and human T-ALL, when combined with either the aurora kinase inhibitor, VX-680,
or the c-Myc inhibitor, JQ1 [47]. mTORC1 inhibitors might be useful also in the context of PTEN-null
T-ALLs treated with the Bcl-2 inhibitor navitoclax (ABT-263), as upregulated mTORC1 increases
the expression levels of myeloid cell leukemia sequence 1 (Mcl-1), thereby mitigating responses to
ABT-263 [158,159] (Figure 1).
7. Conclusions
The evidence gained from the use of knockout models supports the hypothesis that
PTEN-loss-of-function in murine models plays important roles in T-ALL initiation and development.
Similar evidence is still lacking for human T-ALL, although PTEN anomalies seem to be important
for clonal evolution and disease progression. Nevertheless, PTEN loss is crucial to the emergence
of drug-resistance, thereby negatively influencing patient outcome. Our understanding of the
signaling pathways upregulated by PTEN-loss-of-function is growing quite rapidly. Therefore, a
deeper knowledge of the complex oncogenic networks activated by PTEN alterations should provide
promising targeted treatments for improving T-ALL prognosis.
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Bcl-xL B-cell lymphoma-extra large
Bcl-2 B-cell lymphoma 2
Bim Bcl-2-like protein 11
BM Bone marrow
BDNF Brain-derived neurotrophic factor
CCL25 C-C chemokine ligand 25
CCR9 C-C chemokine receptor 9
CK2 Casein kinase 2
c-MYC Avian myelocytomatosis viral homolog
E2f E2 transcription factor
ECM Extracellular matrix
ERK Extracellular signal-regulated kinase
ETP T-ALL Early T-cell precursor T-ALL
Ets E-twenty-six
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4E-BP1 Eukaryotic translation initiation factor 4E-binding protein 1
FAK Focal adhesion kinase
FBXW7 F-box WD repeat-containing protein 7
FLT3 Fms-related tyrosine kinase3
FoxO Forkhead box protein O
GCs Glucocorticoids
GSI γ-secretase inhibitors
GS3Kβ Glycogen synthase kinase 3β
HAVCR2 Hepatitis A virus cellular receptor 2
HES-1 Hairy and enhancer of split-1
HOX Homeobox
HSCs Hematopoietic stem cells
JAK Janus kinase
IRS Insulin receptor substrate
LMO LIM domain only
Mcl-1 Myeloid cell leukemia sequence 1
MEK Mitogen-activated protein kinase kinase
miRs MicroRNAs
MRE11 Meiotic recombination 11 homolog 1
mTOR Mechanistic target of rapamycin
mTORC1 mTOR complex 1
mTORC2 mTOR complex 2
NF-κB Nuclear factor-kB
NOTCH1 Neurogenic locus notch homolog protein 1
NF-κB Nuclear factor kappa B
NR3C1 Nuclear receptor subfamily 3 group C member 1
PDK1 Phosphoinositide-dependent kinase 1
PI3K Phosphatidylinositol-3 kinase
PINK-1 PTEN-induced putative kinase protein 1
PIP2 Phosphatidylinositol(4,5)P2
PIP3 Phosphatidylinositol(3,4,5)P3
PTEN Phosphatase and Tensin homolog, deleted on chromosome TEN
PU.1 PU-box 1 protein
p70S6K 70-kDa ribosomal protein S6 kinase
RAD50 Rad1 homolog 50
RAF Rapidly-accelerated fibrosarcoma
RAG Recombination activating gene
RAS Rat sarcoma
RIP1 Receptor activating protein 1
Rpl24 Ribosome protein L24
ROS Reactive oxygen species
SCL Stem cell leukemia
STIL SCL/TAL1 interrupting locus
SPI1 Spleen focus forming virus proviral integration oncogene 1
STAT3 Signal transducer and activator of transcription 3
T-ALL T-cell acute lymphoblastic leukemia
TAL1 T-cell acute lymphocytic leukemia 1
TCR T-cell receptor
Tcrα/δ-c-Myc T-cell receptor α/δ-c-Myc
TLX Nuclear receptor subfamily 2 group E member
TRK Tropomyosin-related kinase A
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